Microbot Medical Secures China Patent for LIBERTY Robotic System Ahead of Q3 2025 US Launch
核心洞察
Microbot Medical (搜索) received a patent from China's National Intellectual Property Administration covering robotic manipulation of surgical tool handles for its LIBERTY Endovascular Robotic System (搜索).
The company's intellectual property portfolio now includes nine patents granted globally and 59 patent applications pending, strengthening its competitive position in endovascular robotics.
Microbot is preparing for the anticipated Q3 2025 commercial launch of the LIBERTY system in the US market, pending FDA 510(k) clearance.
Microbot Medical (搜索) Inc. (NASDAQ: MBOT) has secured a critical patent in China for its LIBERTY Endovascular Robotic System (搜索), marking a significant milestone in the company's global intellectual property expansion strategy as it prepares for commercial launch in the third quarter of 2025.
The China National Intellectual Property Administration (搜索) (CNIPA) granted the patent covering the robotic manipulation of a surgical tool handle, further validating Microbot's technological innovation in endovascular robotics. This development expands the company's growing intellectual property portfolio, which now encompasses nine patents granted globally and 59 patent applications pending.
Strengthening Global IP Portfolio
The newly granted patent helps ensure Microbot maintains a competitive advantage while protecting the unique capabilities of the LIBERTY System. The single-use, fully disposable endovascular robotic system is designed to assist surgeons in performing minimally invasive procedures within blood vessels, aiming to eliminate traditional barriers to accessing advanced robotic systems.
"As we move closer to our projected U.S. commercial launch of the LIBERTY System, upon planned FDA clearance, we continue to take the necessary steps to build and protect the foundation for sustained growth and global reach," said Harel Gadot, Chairman, CEO & President.
Market Opportunity and Commercial Strategy
The company's primary focus remains on the US market, where it is preparing for the anticipated commercial launch of the LIBERTY Endovascular Robotic System (搜索) in Q3 2025, pending FDA 510(k) clearance. Regulatory, operational and commercial activities are accelerating as the company moves toward this milestone.
Gadot highlighted the significant market opportunity, noting that over two million peripheral endovascular procedures (搜索) are performed annually in the US, with another approximately 2.9 million estimated in China. "We believe the opportunity to impact developed and emerging markets is significant. Expanding access to endovascular robotics is central to our mission to improve patient outcomes and enhance procedural capabilities for physicians worldwide," he stated.
Technology and Development
The LIBERTY system represents what Microbot describes as the world's first single-use, fully disposable endovascular robotic system. This innovative approach targets the minimally invasive surgery space, with the company positioning itself as a pre-commercial stage medical technology company with a vision to redefine endovascular robotics.
While preparing for the US launch, Microbot is simultaneously laying the groundwork to enter international markets and maximize the long-term potential of the LIBERTY system. The company's intellectual property strategy supports this broader global commercialization approach.
The LIBERTY system is currently an investigational device pending FDA 510(k) clearance and is not available for sale in the United States. Microbot Medical (搜索) continues to advance through the regulatory pathway while building its commercial infrastructure for the anticipated market entry.